NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

This study is a single-center, Phase II Study to assess the efficacy and safety of the regimen of Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) in combination with Cadonilimab in subjects with advanced pancreatic ductal adenocarcinoma who have not previously received systemic treatment.

Trial Details

NCT ID

NCT06405490

Phase

PHASE2

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab

Locations (sample)

Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

Age ≥18, male or female;
Has histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC);
Has not received prior systemic treatment for their locally advanced or metastatic PDAC;
Has presence of measurable disease as defined by Response Evaluation Criteria in Solid Tumours (RECIST 1.1);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →